ClinicalTrials.gg
CompletedNCT03660800Updated Sep 30, 2019

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

A Phase 1 interventional study of CTAP101 Capsules in Vitamin D Insufficiency and Secondary Hyperparathyroidism, sponsored by OPKO Health, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by OPKO Health, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2018, 8 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Hyperparathyroidism, Secondary · OPKO Health, Inc..

Enrollment
6th of 13
67 · median 41
Started
2018
with 1 other
Phase 1
4 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc., this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 1, and was the 11th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

1 of the 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc., or all of them as a file.
02

Study summary

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and non-Japanese Healthy Subjects

Read the detailed description

An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and non-Japanese Healthy Subjects

03

Conditions studied

  • Vitamin D Insufficiency
  • Secondary Hyperparathyroidism
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Signed the form as described in Appendix 3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  2. Willing and able to comply with study instructions and to commit to all study days
  3. Man or woman, 18 to 55 years of age inclusive at the time of signing the informed consent form
  4. Overtly healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests
  5. (BMI) within 18.0 to 30.0 kg/m2 (inclusive) and body weight not less than 50 kg
  6. Blood pressure (after at least 2 minutes of rest) between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic.
  7. A 12-lead consistent with normal cardiac conduction and function, including:

    • Sinus rhythm
    • Pulse rate between 40 and 100 beats per minute (bpm)
    • ≤450 milliseconds (QT interval corrected using Fridericia correction method [QTcF]
    • QRS interval of \<120 milliseconds
    • PR interval \<200 milliseconds
    • Morphology consistent with healthy cardiac conduction and function
  8. Must have negative tests for drugs of abuse at Screening and Day -2
  9. Must have a negative alcohol test at Screening and Day -2
  10. Must have adequate venous access in both arms, in the opinion of the Investigator
  11. Has a screening serum total 25-hydroxyvitamin D level between 10 and 40 ng/mL, inclusive
  12. If male, must agree to use as detailed in Appendix 5 of this protocol during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period
  13. If female, be sterile (ie, at least 1 month post-surgical sterilization, confirmed nonsurgical sterilization or at least 6 months [as determined by follicle stimulating hormone (FSH) / estradiol testing]); or who are of but are abstinent, have a surgically sterile partner (ie, at least 6 months postvasectomy), or are using a copper intrauterine device or a combination of at least 2 acceptable barrier methods such as condom + intravaginal spermicide, diaphragm + intravaginal spermicide, or cervical cap + intravaginal spermicide. Contraceptive medications (oral or by other routes) containing hormones are not allowed. Women of childbearing potential must not be lactating and must have a negative pregnancy test at screening and Day -2, and agree to continue their accepted method of contraception throughout the study. See guidance on contraceptives in Appendix 5. Additional Inclusion Criteria for Japanese Participants Only
  1. Be first generation Japanese defined as:
  • Born in Japan
  • Has 2 Japanese biological parents and 4 Japanese biological grandparents
  • Has lived outside of Japan for less than 5 years
  • Has made no significant changes in lifestyle, including diet, since leaving Japan Additional Inclusion Criteria for non-Japanese Participants Only

    1. Not of Japanese or Asian descent
    2. Parents and grandparents not born in Japan or in any Asian countries Note: Retesting of abnormal lab values that may lead to exclusion will be allowed once.

Retesting will take place during an unscheduled visit during the screening phase.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Has taken a Vitamin D supplement within 28 days prior to dosing
  2. Has a medically confirmed history of kidney stones within the previous 2 years
  3. Has a urine calcium: creatinine ratio > 0.2 at the Screening visit
  4. Has a known or suspected to any of the constituents of the products
  5. Has a history of or current medical illness including but not limited to, cardiac arrhythmias or other cardiac disease; hematologic disease; coagulation disorders (including any abnormal bleeding or blood dyscrasias); lipid abnormalities; significant pulmonary disease, including bronchospastic respiratory disease; diabetes mellitus; hepatic or renal insufficiency ( below 60 mL/min); thyroid disease; neurologic or psychiatric disease; infection; or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results.
  6. Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening as deemed appropriate by the investigator
  7. Clinically significant abnormal physical examination, vital signs or 12 lead at screening as deemed appropriate by the investigator
  8. Has a history of (HIV) antibody positive, or tests positive for HIV; has a history of surface antigen (HBsAg) or antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening.
  9. Has received an investigational drug or used an invasive investigational medical device within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before Day 1.
  10. Has donated 1 unit (450 mL) or more of blood or plasma within 30 days of dosing
  11. Has an acute illness within 5 days prior to the first dose of study medication
  12. Has received any prescribed systemic or topical medication within 14 days of dosing, received a vaccination within 30 days of dosing, or taken any nonprescription systemic or topical medication or herbal preparation within 7 days of dosing (exception: occasional use of acetaminophen or ibuprofen at nonprescription doses).
  13. History of drug or alcohol use disorder according to (5th edition) criteria within 5 years before Screening or positive test result(s) for alcohol and/or drugs of abuse (including prescription drugs such as stimulants, opioids, and benzodiazepines) at Screening or at Admission on Day -2
  14. Has an (ALT) or aspartate aminotransferase (AST) level >1.5 times the (ULN), active liver disease or jaundice at Screening or Day -2
  15. Is considering or has preplanned surgery or procedures that would interfere with the conduct of the study
  16. Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    CTAP101 Capsules 450mcg/weekly fasted

    Drug: CTAP101 Capsules

  • Experimental
    CTAP101 Capsules 900mcg/weekly fasted

    Drug: CTAP101 Capsules

  • Experimental
    CTAP101 Capsules 1800mcg/weekly fasted

    Drug: CTAP101 Capsules

  • Experimental
    CTAP101 Capsules 900mcg/weekly fed

    Drug: CTAP101 Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related AEs as assessed by industry standards

    Incidence of AEs will be summarized by arm for all treatment-emergent AEs. Number and percent of participants with AEs will be summarized by system organ class and preferred term and presented overall and by arm.

    Time frame: 8 weeks

  2. Change in baseline of peak plasma concentration

    Baseline finding will be measured against the different time points collected

    Time frame: 8 weeks

  3. Change in mean total of the different components of calcifediol

    Descriptive statistics will be calculated for PD assessment in the per protocol population.

    Time frame: 8 weeks

07

Study locations

1 site
  • WCCT Global, Inc.
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Sep 7, 2018
StartActual
Aug 20, 2018
Primary completionActual
Oct 24, 2018
CompletionActual
Jan 22, 2019
Last update
Sep 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03660800
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Aug 20, 2018
Primary completion
Oct 24, 2018
Completion
Jan 22, 2019
Last update
Sep 30, 2019

Study contacts

Jeremy Mussallem
study chair · WCCT Global, Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modified-release Calcifediol Capsule

Start the discussion